Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sintilimab - Eli Lilly and Company/Innovent Biologics

Drug Profile

Sintilimab - Eli Lilly and Company/Innovent Biologics

Alternative Names: Anti-PD-1 antibody - Eli Lilly and Company/Innovent Biologics; IBI 308; LY-3342901; Sintilimab injection; Sintilimab injection - Eli Lilly and Company/Innovent Biologics; Tyvyt; Xindili Dankang

Latest Information Update: 26 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Adimab; Innovent Biologics
  • Developer Chinese Academy of Medical Sciences; Eli Lilly and Company; Fujian Cancer Hospital; HUTCHMED; Innovent Biologics; Jiangsu Hengrui Medicine Co.; Jiangsu Provincial Peoples Hospital; Laekna Therapeutics; Peking University; Shanghai Jiaotong University School of Medicine; Sun Yat-Sen University; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 receptor antagonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Gastric cancer; Hodgkin's disease; Liver cancer; Non-small cell lung cancer; Oesophageal cancer
  • Phase III Acral lentiginous melanoma; Nasopharyngeal cancer
  • Phase II/III Colorectal cancer; Renal cell carcinoma
  • Phase II Cancer; Cervical cancer; Extranodal NK-T-cell lymphoma; Neuroendocrine tumours; Small cell lung cancer
  • Phase I/II Solid tumours
  • Phase I Lung cancer; Lymphoma

Most Recent Events

  • 26 Mar 2024 Registered for Non-small cell lung cancer in Macau (IV)
  • 28 Dec 2023 Innovent Biologics and Xuanzhu Biopharmaceutical agree to co-develop combination of KM 501 and Sintilimab in China for Solid tumours
  • 28 Dec 2023 Xuanzhu Biopharmaceutical and Innovent Biologics plans a phase-Ib trial for Solid tumours (Combination therapy, Late-stage disease) in China (Parenteral)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top